article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

Up until 2023 around 600 NK cell clinical trials have been reported and some 200 are clinically active and still recruiting patients. The vast majority (65/74; 88%) of those trials involved NK cells without CARs; while only 12 percent were CAR-NK studies. CAR-NK cell trials only commenced in 2017 and most are still recruiting patients.

Therapies 118
article thumbnail

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers’Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects

The Pharma Data

Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers. development pipeline for ME/CFS. All study subjects will receive the same Ampligen treatments.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Preclinical research on γδ T cells has made great strides since the cells were first identified in the 1980s, with γδ T-cell therapies from several companies, including IN8bio, now in or nearing clinical trials for various cancers. from 2003 to 2006, covering the biotechnology and life-science tools sectors.

Therapies 105
article thumbnail

New drug boosts foetal haemoglobin to fight sickle cell disease

Drug Target Review

Results of the Multicenter Study of Hydroxyurea in Sickle Cell Anaemia published in the Journal of the American Medical Association in 2003, indicated that the use of hydroxyurea, the only drug approved at the time, reduced mortality as it reduced pain crises and increased foetal haemoglobin.

Disease 80
article thumbnail

Nirsevimab demonstrated protection against respiratory syncytial virus disease in healthy infants in Phase 3 trial

The Pharma Data

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. The overall safety profile of nirsevimab in the trial remains consistent with previously reported results. Lurie Children’s Hospital of Chicago, Illinois, US and primary investigator of the MELODY Phase III trial.

Virus 40
article thumbnail

Women in Stem with Andrea Pfeifer

Drug Target Review

Then I was approached to co-found AC Immune in 2003. We are the only company in the world including this population in any Alzheimer’s drug trial, and we are very proud of this! I accepted and I’ve been CEO ever since; our goal, from the beginning, was to pioneer new ways to diagnose, treat and prevent neurodegenerative diseases.

Disease 95
article thumbnail

New understanding of the TMEJ pathway in cancer

Drug Target Review

In 2003, Dr Richard Wood, distinguished Professor at the University of Texas MD Anderson Cancer Center, was a crucial part of the first characterisation of polymerase theta. His and Dr Stroik’s new research will help new cancer drugs called polymerase theta inhibitors, which are currently in clinical trials. Annual Review of Genetics.

DNA 59